UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Journal of clinical oncology, 2017-02, Vol.35 (4), p.412-420

2017

Volltextzugriff (PDF)

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Cancer cell, 2022-03, Vol.40 (3), p.289-300.e4

2022

Volltextzugriff (PDF)

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers

Cell reports (Cambridge), 2016-09, Vol.16 (10), p.2605-2617

2016

Volltextzugriff (PDF)

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

Molecular cell, 2019-12, Vol.76 (5), p.838-851.e5

2019

Volltextzugriff (PDF)

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Cancer cell, 2011-08, Vol.20 (2), p.158-172

2011

Volltextzugriff (PDF)

Analytical evaluation of circulating tumor DNA sequencing assays

Scientific reports, 2024-02, Vol.14 (1), p.4973-4973, Article 4973

2024

Volltextzugriff (PDF)

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

PloS one, 2009-10, Vol.4 (10), p.e7464-e7464

2009

Volltextzugriff (PDF)

Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis

Respirology (Carlton, Vic.), 2012-10, Vol.17 (7), p.1048-1059

2012

Volltextzugriff (PDF)

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

Nature (London), 2010-05, Vol.465 (7297), p.473-477

2010

Volltextzugriff (PDF)

Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations

Molecular cancer research, 2013-06, Vol.11 (6), p.638-650

2013

Volltextzugriff (PDF)

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

The lancet respiratory medicine, 2017-05, Vol.5 (5), p.435-444

2017

Volltextzugriff (PDF)

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Scientific reports, 2021-07, Vol.11 (1), p.13912-13912, Article 13912

2021

Volltextzugriff (PDF)

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2040-2050

2021

Volltextzugriff (PDF)

A Translational View of the Molecular Pathogenesis of Lung Cancer

Journal of thoracic oncology, 2007-04, Vol.2 (4), p.327-343

2007

Volltextzugriff (PDF)

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

Lung cancer (Amsterdam, Netherlands), 2018-12, Vol.126, p.1-8

2018

Volltextzugriff (PDF)

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy

Molecular cancer therapeutics, 2011-02, Vol.10 (2), p.336-346

2011

Volltextzugriff (PDF)

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

International journal of cancer, 2012-04, Vol.130 (8), p.1733-1744

2012

Volltextzugriff (PDF)

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Clinical cancer research, 2015-06, Vol.21 (11), p.2462-2470

2015

Volltextzugriff (PDF)

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

Clinical cancer research, 2013-12, Vol.19 (24), p.6912-6923

2013

Volltextzugriff (PDF)

NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM

Proceedings of the National Academy of Sciences - PNAS, 2013-04, Vol.110 (16), p.6524-6529

2013

Volltextzugriff (PDF)

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

Molecular cancer therapeutics, 2009-07, Vol.8 (7), p.1761-1771

2009

Volltextzugriff (PDF)

The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma

International journal of cancer, 2012-12, Vol.131 (12), p.2820-2831

2012

Volltextzugriff (PDF)

1 – 25 von 369

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(354)
Mit Volltextzugriff
(315)

Publikationsform

Sprache

Englisch
(368)
Japanisch
(68)

Erscheinungsjahr

n.n

Thema

Science & Technology
(221)
Life Sciences & Biomedicine
(202)
Humans
(150)
Female
(106)
Animals
(96)
Radiology, Nuclear Medicine & Medical Imaging
(64)
Male
(63)
Biological And Medical Sciences
(59)
Rats
(59)
Oncology
(54)
Medical Sciences
(47)
Middle Aged
(45)
Adult
(40)
Contrast Media
(38)
Tumors
(38)
Magnetic Resonance Imaging
(37)
Lung Neoplasms - Genetics
(36)
Lung Cancer
(34)
Magnetic Resonance Imaging - Methods
(31)
Aged
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Analytical evaluation of circulating tumor DNA sequencing assays

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

A Translational View of the Molecular Pathogenesis of Lung Cancer

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma

Suchergebnisse filtern